Man Group plc trimmed its holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP by 80.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,742 shares of the biotechnology company's stock after selling 79,629 shares during the quarter. Man Group plc's holdings in Aurinia Pharmaceuticals were worth $177,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Kingswood Wealth Advisors LLC acquired a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at approximately $248,000. Union Bancaire Privee UBP SA acquired a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at approximately $108,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Aurinia Pharmaceuticals by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 30,359 shares of the biotechnology company's stock valued at $273,000 after acquiring an additional 2,857 shares during the period. Blue Trust Inc. boosted its holdings in shares of Aurinia Pharmaceuticals by 3,041.4% in the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company's stock valued at $57,000 after acquiring an additional 6,174 shares during the period. Finally, Atria Wealth Solutions Inc. acquired a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at approximately $135,000. 36.83% of the stock is owned by institutional investors and hedge funds.
Insider Activity
In other news, insider Greg Keenan sold 8,305 shares of Aurinia Pharmaceuticals stock in a transaction on Friday, March 7th. The stock was sold at an average price of $8.23, for a total value of $68,350.15. Following the completion of the sale, the insider now owns 153,484 shares of the company's stock, valued at $1,263,173.32. The trade was a 5.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Peter Greenleaf sold 195,593 shares of Aurinia Pharmaceuticals stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $1,564,744.00. Following the completion of the sale, the chief executive officer now directly owns 1,953,892 shares of the company's stock, valued at approximately $15,631,136. This represents a 9.10% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 343,898 shares of company stock valued at $2,753,094 over the last quarter. Company insiders own 12.20% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, Wall Street Zen raised Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Thursday, March 27th.
Get Our Latest Analysis on Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Price Performance
NASDAQ:AUPH traded up $0.01 during trading hours on Thursday, hitting $7.99. The company's stock had a trading volume of 1,036,416 shares, compared to its average volume of 1,335,968. The business's 50-day moving average is $8.00 and its two-hundred day moving average is $8.27. The company has a market capitalization of $1.08 billion, a PE ratio of -53.26 and a beta of 1.16. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. Aurinia Pharmaceuticals Inc. has a 52-week low of $5.15 and a 52-week high of $10.67.
Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.16 EPS for the quarter, beating analysts' consensus estimates of $0.08 by $0.08. The business had revenue of $62.47 million during the quarter, compared to the consensus estimate of $61.06 million. Aurinia Pharmaceuticals had a negative return on equity of 4.41% and a negative net margin of 10.23%. As a group, research analysts anticipate that Aurinia Pharmaceuticals Inc. will post 0.11 EPS for the current fiscal year.
Aurinia Pharmaceuticals Profile
(
Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Featured Stories
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
